Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 83,094 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 83,094 shares of Immunome stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $24.11, for a total value of $2,003,396.34. Following the completion of the transaction, the director owned 125,410 shares of the company’s stock, valued at approximately $3,023,635.10. This represents a 39.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Tuesday, July 7th, Isaac Barchas sold 16,906 shares of Immunome stock. The shares were sold at an average price of $24.20, for a total value of $409,125.20.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total value of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The stock was sold at an average price of $21.12, for a total value of $2,134,176.00.

Immunome Stock Performance

NASDAQ IMNM opened at $24.39 on Wednesday. The company has a market cap of $2.76 billion, a P/E ratio of -10.25 and a beta of 2.07. The business’s 50 day moving average price is $20.99 and its 200-day moving average price is $21.83. Immunome, Inc. has a fifty-two week low of $7.96 and a fifty-two week high of $27.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, equities analysts predict that Immunome, Inc. will post -2.06 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Leerink Partners dropped their target price on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Immunome in a research note on Wednesday, May 13th. Wedbush restated an “outperform” rating and set a $31.00 price objective on shares of Immunome in a report on Friday, June 12th. Barclays began coverage on Immunome in a research report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.17.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently modified their holdings of IMNM. T. Rowe Price Investment Management Inc. grew its stake in Immunome by 59.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after purchasing an additional 5,003,824 shares in the last quarter. Vanguard Group Inc. raised its position in Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock valued at $129,705,000 after purchasing an additional 1,144,788 shares in the last quarter. Primecap Management Co. CA lifted its holdings in shares of Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock worth $100,643,000 after buying an additional 1,667,432 shares during the period. State Street Corp lifted its holdings in shares of Immunome by 37.9% in the 4th quarter. State Street Corp now owns 3,868,000 shares of the company’s stock worth $83,085,000 after buying an additional 1,064,027 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Immunome by 8,659.2% during the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock worth $61,341,000 after buying an additional 2,823,144 shares in the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.